Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|September 2, 1998

Syncor signs Israeli radiopharmacy deal

Radiopharmacy firm Syncor International of Woodland Hills, CA, has agreed to license its technology to Israeli nuclear research agency Soreq and its subsidiary, Isorad, which plan to establish a radiopharmacy in Israel. In exchange for providing

Radiopharmacy firm Syncor International of Woodland Hills, CA, has agreed to license its technology to Israeli nuclear research agency Soreq and its subsidiary, Isorad, which plan to establish a radiopharmacy in Israel. In exchange for providing information and technical assistance to set up the radiopharmacy, Syncor will receive quarterly payments. Soreq is affiliated with the Israel Atomic Energy Commission and carries out advanced R&D projects, while Isorad sells and markets Soreq products to private businesses.


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.